

EISAI SIGNS AGREEMENT WITH EPIZYME AND ROCHE MOLECULAR SYSTEMS TO DEVELOP COMPANION DIAGNOSTIC

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ~~03-6363-1111~~) announced today that it has signed an agreement with Epizyme, Inc. (Headquarters: Massachusetts, the United States; President & CEO: Robert Gould; ~~978-234-1111~~) and Roche Molecular Systems Inc. (Headquarters: California, the United States; CEO: Paul Brown; ~~916-276-1111~~) to collaborate on the development of a companion diagnostic to help Eisai and Epizyme identify patients for their research on lymphomas. Specifically, the new companion diagnostic will further enable Eisai and Epizyme to advance personalized therapeutics for patients with lymphomas possessing genetic mutations in the epigenetic enzyme EZH2.

Since April 2011, Eisai has collaborated with Epizyme under a strategic partnership agreement focused on the development of cancer therapies that target EZH2 and been engaging in research aimed at the creation of such therapies. As demo

[Notes to editors]

1.